WHO suspends hydroxychloroquine trials over safety concerns
A Lancet study leads to a rethink of using the drug to treat coronavirus patients - but an Australian prophylaxis trial will continue
The WHO has suspended its multinational trial of hydroxychloroquine to treat patients with COVID-19, amid growing evidence the drug increases the risk of death.
The move follows a study published in the Lancet last week showing the drug, which is indicated for treatment of malaria and autoimmune conditions, had no therapeutic benefit against COVID-19 and did more harm than good.
